Opinion

Video

BOND-003 Trial and Cretostimogene for Treatment of NMIBC

Panelists discuss how cretostimogene grenadenorepvec is an intravesical oncolytic virus therapy targeting BCG-unresponsive bladder cancer through selective replication in tumor cells and immune stimulation via granulocyte-macrophage colony-stimulating factor expression.

Video content above is prompted by the following:

  • What is cretostimogene grenadenorepvec? Please describe its mechanism of action.
  • Discuss the phase 3 BOND-003 clinical trial investigating the use of the intravesical immunotherapy cretostimogene grenadenorepvec in patients with high-risk, BCG-unresponsive disease that was recently presented at the Society of Urologic Oncology 2024.
  • What are your impressions of the BOND-003 data?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Urology Times Mitomycin RX Review Square Thumb
Urology Times Mitomycin RX Review Square Thumb
© 2025 MJH Life Sciences

All rights reserved.